1. PARP Inhibition: The New Frontier in Recurrent Ovarian Cancer

2. Program Goals

4. BRCA Testing in Ovarian Cancer NCCN, ASCO, ESMO, SGO Guidance

5. Olaparib: FDA Accelerated Approval

6. Olaparib Indications: US vs Europe

7. PARP Inhibitors: Common Adverse Events

8. Supportive Care to Maintain Patients on PARPi

9. Ongoing PARP Inhibitor Trials

10. Proposed Front-line Veliparib Study (GOG 3005)

12. Olaparib Plus Cediranib

13. PARPi Combinations: Recurrent Ovarian Cancer

14. Homologous Recombination Deficiency and "BRCAness"

15. ARIEL2: Rucaparib Sensitivity According to Prospectively Defined Molecular Subgroups

16. ARIEL2: Response by HRD Status

17. Abbreviations

18. Abbreviations (cont)

19. Abbreviations (cont)

20. References

21. References (cont)

22. References (cont)

23. References (cont)

24. References (cont)

25. References (cont)

26. References (cont)

27. References (cont)

28. References (cont)